Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences Co., Ltd, a Beijing-based biotech specializing in applying bioinformatics, genomics, and cutting-edge internet technologies to clinical medicine and personal health, have signed a long-term collaboration agreement. The partnership aims to integrate short-read sequencing and long-read sequencing resources to set up an ultra-high throughput integrated sequencing service laboratory in the China (Shanghai) Pilot Free Trade Zone.
Ultra-High Throughput Integrated Sequencing Service Laboratory
The laboratory will provide research solutions for disease mechanism, species discovery and identification, immunization, and vaccine development. This collaboration will leverage the strengths of both companies to offer comprehensive services to pharmaceutical enterprises, biotechnology companies, and academic research institutions. No financial details of the collaboration were disclosed.
Sequanta Technologies: Service Offerings
Sequanta, which boasts a 3,000 square meter central laboratory and a large high-throughput sequencing platform, provides service support for disease pathogenesis research, target and biomarker discovery, and standardized detection. The company’s extensive capabilities make it a valuable partner for the development of integrated sequencing services.
Grandomics Biosciences: Long-Read Sequencing Expertise
Grandomics, a long-read sequencing technology and service provider, consists of “Grandomics Research Services,” “Grandomics Clinical Services,” “Grandomics Bioinformatics,” and “Grandomics Advanced Manufacturing.” The company provides world-leading PacBio HiFi sequencing services, which will be a key component of the ultra-high throughput integrated sequencing service laboratory.-Fineline Info & Tech
